The Asia-pacific market for Nuclear Medicine Radiopharmaceuticals is estimated at $1.25 billion in 2019 and is expected to reach $2.43 billion by 2024, growing at a CAGR of 14.3%.
Nuclear medicine falls under the field of Molecular imaging, which involves the usage of minute amounts of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
Drivers and Restraints
Increasing incidence of chronic diseases such as cancer and cardiac ailments, advancements in technology, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the growth of the market. Further, new developments such as the Integration of X-ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. A strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Asia-Pacific nuclear medicine Radioisotopes market.
India and China hold a potential market for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications.
Diagnostic Radioisotopes is the dominating segment and accounts for around 90 % of the radiopharmaceuticals market while therapeutic radioisotopes contribute 10% of the market. Based on the type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have been gaining the business interest of major research institutes and PET isotope players in recent times. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring the high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
This research report segmented and sub-segmented into the following categories:
Leading companies in the Asia-Pacific nuclear medicine Radiopharmaceuticals:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Diagnostic Radioisotopes
5.1.1.1 SPECT
5.1.1.1.1 Technetium-99m
5.1.1.1.2 Thallium-201
5.1.1.1.3 Gallium-67
5.1.1.1.4 Iodine-23
5.1.1.1.5 Others
5.1.1.2 PET
5.1.1.2.1 Fluorine-18
5.1.1.2.2 Rubidium-82
5.1.1.2.3 Others
5.1.2 Therapeutic Radioisotopes
5.1.2.1 Beta Emitters
5.1.2.1.1 Iodine-131
5.1.2.1.2 Yttrium-90
5.1.2.1.3 Samarium-153
5.1.2.1.4 Rhenium-186
5.1.2.1.5 Lutetium-177
5.1.2.2 Alpha Emitters
5.1.2.2.1 Radium-223
5.1.2.3 Brachytherapy
5.1.2.3.1 Cesium-131
5.1.2.3.2 Iodine-125
5.1.2.3.3 Palladium-103
5.1.2.3.4 Iridium-192
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hologic Inc.
8.3 Segami Corporation
8.4 Positron Corporation
8.5 Bracco Imaging S.P.A
8.6 Naviscan Inc.
8.7 Bayer Healthcare
8.8 Lantheus Medical Imaging Inc.
8.9 IBA Molecular Imaging
8.10 Medix Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
